News

Thursday July 28, 2022

Chair’s Investor Update

Destiny Pharma plc (AIM: DEST), a clinical stage biotechnology company focused on the development of novel products to prevent life-threatening infections, today announces an Investor Update from its Chair, Nick […]

Thursday July 28, 2022

Chair’s Investor Update

Destiny Pharma plc (“Destiny Pharma” or “the Company”) Chair’s Investor Update Brighton, United Kingdom – 28 July 2022 – Destiny Pharma plc (AIM: DEST), a clinical stage biotechnology company focused […]

Tuesday July 26, 2022

Publication of new data on NTCD-M3

Destiny Pharma plc (AIM: DEST), a clinical stage biotechnology company focused on the development of novel products to prevent life-threatening infections, today announces publication of new data on NTCD-M3, its […]

Tuesday July 26, 2022

Publication of new data on NTCD-M3

Destiny Pharma plc (“Destiny Pharma” or “the Company”) Publication of new data on NTCD-M3 confirms potential as an effective treatment for prevention of C. difficile infections Brighton, United Kingdom – 26 July 2022 […]

Tuesday July 19, 2022

Positive update from US FDA on XF-73 Phase 3

Destiny Pharma plc (“Destiny Pharma” or the “Company”) Destiny Pharma announces positive update from US FDA on XF-73 Phase 3 development plans FDA clarifies Phase 3 and US registration pathway […]

Tuesday July 12, 2022

Destiny Pharma receives award from the Cystic Fibrosis Foundation

Destiny Pharma plc (“Destiny Pharma” or “the Company”) Destiny Pharma receives award from the Cystic Fibrosis Foundation Study to investigate potential of XF-73 to treat MRSA infection in people with […]

Thursday July 7, 2022

Destiny Pharma announce publication of XF-73 drug synergy data

Destiny Pharma plc (“Destiny Pharma” or “the Company”) Destiny Pharma announces publication of XF-73 drug synergy data XF-73 shown to enhance the activity of two antibacterial drugs Findings may lead […]

Tuesday July 5, 2022

Destiny Pharma announces start of a new XF-73 research programme

Destiny Pharma plc (“Destiny Pharma” or the “Company”) Destiny Pharma announces start of a new XF-73 research programme Aim to test XF-73 as a potential preventive medicine for Oral Mucositis […]